One of the greatest challenges in drug development is ensuring that active pharmaceutical ingredients (APIs) reach their target in the body at the right place, in the right dosage, and at the right time.
While oral administration is the most convenient and most preferred route for patients, many promising APIs face critical limitations: degradation in the harsh environment of the digestive tract or insufficient absorption across the intestinal barrier. These issues lead to poor bioavailability, preventing their full therapeutic potential from being realized.
Through Lipidosa, NovoArc aims to unlock new possibilities for stable and efficient oral drug delivery by leveraging our unique tetraether lipid technology.
